Bacil Pharma Limited has submitted its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31st March 2026. The pharmaceutical company filed the certificate with BSE Limited on 14th April 2026, demonstrating its adherence to regulatory requirements.

Regulatory Compliance Certificate

The certificate was issued by Bigshare Services Pvt. Ltd., the company's Registrar and Transfer Agent, on 6th April 2026. The document confirms that Bacil Pharma Limited has fulfilled all necessary obligations under the SEBI depositories regulations for the quarter ended 31st March 2026.

Key Compliance Confirmations

The certificate validates three critical compliance areas:

• Securities Listing Verification: All securities comprised in dematerialized certificates have been properly listed on stock exchanges where the company's earlier issued securities are traded
• Certificate Cancellation: Physical certificates received for dematerialization have been mutilated and cancelled after due verification by the depository participant
• Record Maintenance: The depository's name has been substituted in the register of members as the registered owner within the stipulated 15-day timeline

Documentation Details

The submission was signed by Mrs. Chaitali Kalpataru Shah, Director of Bacil Pharma Limited, with DIN 11167778. The certificate references SEBI circulars dated 25th January 2019 and related regulatory guidelines that mandate quarterly reporting of dematerialization activities.

Company Information

Bacil Pharma Limited operates from its registered office at G2 & G3 Samarpan Complex, Next to Mirador Hotel, Chakala, Andheri East, Mumbai. The company maintains its compliance obligations through Bigshare Services Pvt. Ltd., which serves as its Registrar and Transfer Agent for all depositories-related activities.

Bacil Pharma Limited has responded to BSE Limited's inquiry regarding significant movement in its stock price, clarifying that no unpublished price sensitive information exists that could explain recent trading activity. The company submitted its formal response on February 24, 2026, addressing BSE's clarification request under reference number L/SURV/ONL/PV/SJ/2025-2026/3393.

Company's Position on Price Movement

The pharmaceutical company categorically stated that it is not in possession of any unpublished price sensitive information or material developments that could have influenced recent price or trading volume movements. The response emphasized that no proposed announcements or events are pending that would warrant such market activity.

Regulatory Compliance Confirmation

Bacil Pharma confirmed full compliance with Regulation 30 and all applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company stated that all material events and information requiring disclosure have been communicated to the stock exchange within prescribed timelines.

Market-Driven Fluctuations

The company attributed recent stock price fluctuations to purely market-driven factors. This assessment suggests that external market conditions, rather than company-specific developments, are responsible for the observed price movements that prompted BSE's inquiry.

Corporate Governance Commitment

Bacil Pharma reaffirmed its commitment to maintaining high standards of corporate governance and transparency. The company emphasized its dedication to timely disclosure of material information as required under applicable laws and regulations. Director Chaitali Kalpataru Shah digitally signed the response, reinforcing the company's formal commitment to regulatory compliance and stakeholder transparency.